| Trial ID: | L7306 |
| Source ID: | NCT01572753
|
| Associated Drug: |
Semaglutide
|
| Title: |
Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2|Healthy
|
| Interventions: |
DRUG: semaglutide|DRUG: semaglutide|DRUG: semaglutide|DRUG: semaglutide|DRUG: semaglutide|DRUG: semaglutide|DRUG: semaglutide|DRUG: semaglutide
|
| Outcome Measures: |
Primary: AUC 0-24h; Area under the semaglutide concentration curve from time 0-24 hours after the 10th dosing, 0-24hrs after the 10th dosing | Secondary: Cmax; The maximum plasma semaglutide concentration, Post-dose at day 10|tmax; Time to maximum plasma semaglutide concentration, Post-dose at day 10|t1/2; the terminal half-life of semaglutide, Post-dose at day 10
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
MALE
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
161
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2012-04-12
|
| Completion Date: |
2012-09-08
|
| Results First Posted: |
|
| Last Update Posted: |
2017-02-27
|
| Locations: |
Novo Nordisk Investigational Site, Berlin, 14050, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT01572753
|
